Study of Telaprevir in Subjects With Hepatic Impairment

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00509210

Enrollment

Unknown

Registered

2007-07-31

Start date

2007-09-30

Completion date

2008-06-30

Last updated

2008-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatic Insufficiency

Keywords

Liver Disease

Brief summary

The purpose of this study is to assess the safety and pharmacokinetics of Telaprevir following administration of multiple oral doses to subjects with moderate and severe hepatic impairment.

Interventions

DRUGtelaprevir (VX-950)

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Clinically diagnosed with Child Pugh score of 7-9 or greater than 10 * Women of non-childbearing age

Exclusion criteria

* Tested positive for HIV, Hepatitis C, Hepatitis B

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026